By determining HLA phenotype before drug introduction, the incidence of DIE was dramatically reduced, since none of the 4,120 HLA-B*1502 negative included patients developed SJS, TEN, or DRESS compared to an estimation of 10 expected SJS and TEN cases. This evidence concerns the gene HLA-B and toxic epidermal necrolysis.